Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell Responses: IFN-Gamma Aids TLR Stimulation. by Sheng, KC et al.
Hindawi Publishing Corporation
Journal of Drug Delivery
Volume 2013, Article ID 516749, 9 pages
http://dx.doi.org/10.1155/2013/516749
Research Article
Enhanced Dendritic Cell-Mediated Antigen-Specific CD4+ T Cell
Responses: IFN-Gamma Aids TLR Stimulation
Kuo-Ching Sheng,1,2 Stephanie Day,1,3 Mark D. Wright,3
Lily Stojanovska,4 and Vasso Apostolopoulos1,5
1 Immunology and Vaccine Laboratory, Burnet Institute, Melbourne, VIC 3004, Australia
2 Institute for Glycomics, Griffith University, Gold Coast, QLD 4215, Australia
3 Department of Immunology, Monash University, Melbourne, VIC 3004, Australia
4College of Health and Biomedicine, Victoria University, VIC 3021, Australia
5 VA Consulting Services, Melbourne, VIC 3030, Australia
Correspondence should be addressed to Mark D. Wright; mark.wright@monash.edu and
Vasso Apostolopoulos; vasso@scientist.com
Received 12 December 2012; Accepted 18 February 2013
Academic Editor: Theresia Thalhammer
Copyright © 2013 Kuo-Ching Sheng et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Phenotypic maturation and T cell stimulation are two functional attributes of DCs critical for immune induction.The combination
of antigens, including those from cancer, with Toll-like receptor (TLR) ligands induces far superior cellular immune responses
compared to antigen alone. In this study, IFN-gamma treatment of bone marrow-derived DC, followed by incubation with the
TLR2, TLR4, or TLR9 agonists, enhanced DC activation compared to TLR ligation alone. Most notably, the upregulation of CD40
with LPS stimulation and CD86 with CpG stimulation was observed in in vitro cultures. Similarly, IFN-gamma coinjected with
TLR ligands was able to promote DC activation in vivo, with DCs migrating from the site of immunization to the popliteal lymph
nodes demonstrating increased expression of CD80 and CD86. The heightened DC activation translated to a drastic increase in T
cell stimulatory capacity in both antigen independent and antigen dependent fashions. This is the first time that IFN-gamma has
been shown to have a combined effect with TLR ligation to enhance DC activation and function.The results demonstrate the novel
use of IFN-gamma together with TLR agonists to enhance antigen-specific T cell responses, for applications in the development of
enhanced vaccines and drug targets against diseases including cancer.
1. Introduction
Vaccination requires highly purified proteins or synthetic
peptides usually in combination with immune stimulating
adjuvants or danger signals, to successfully prime T cells.
In the last 10 years, there has been an upsurge of data
suggesting that dendritic cells (DCs) are the most important
cells to stimulate immune responses against antigens [1].
DCs link the innate and adaptive immune responses by
(i) binding a vast array of pathogens through their cell
surface receptors, includingC-type lectins, Toll-like receptors
(TLRs), and scavenger receptors and inducing inflammatory
responses for their elimination and (ii) are able to stimulate
CD4+ T cell responses and cross present antigens for CD8+
T cell stimulation against antigens. Numerous strategies
have been utilized to target antigens to DCs, following the
abundance of information becoming available regarding cell
surface expression of receptors and their role in stimulating
immune responses [2]. The mannose receptor, DC-SIGN,
scavenger receptor, DEC-205, and Toll-like receptors (TLRs)
are amongst the most thoroughly studied DC receptors [2].
Targeting of these receptors is becoming an effective strategy
of delivering antigens in DC-based anticancer immunother-
apy studies.
TLRs are a class of proteins (pathogen recognition recep-
tors, PRRs) that play a key role in the innate immune system
and recognize molecules derived from pathogens (bacteria,
fungi, virus, parasitic protozoa, mycoplasma), leading to
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stimulation of immune responses. Toll was first identified,
almost 20 years ago, when it was found to have an essential
role in the fly’s immunity to fungal infections [3] and
the first human TLR (TLR1) to be identified immediately
followed [4].Three years later, it was demonstrated that TLR4
initiated an adaptive immune response following ligation
of the receptor with antibody [5], and lipopolysaccharide
(LPS) was found to be the main ligand for TLR4 [6].
Using a series of gene ablations in mice, identification of
other TLRs followed, mainly by Akira and colleagues [7–
9], and to date 13, TLRs (TLR1-TLR13) have been iden-
tified. In brief, the ligands for each TLR are lipopeptides
(TLR1), glycolipids, lipoproteins, heat shock protein (HSP)-
70, zymosan (TLR2), double strandedRNA, poly I : C (TLR3),
LPS, several HSPs (TLR4), flagellin (TLR5), multiple diacyl
lipopeptides (TLR6), imidazoquinoline, loxoribine, bropir-
imine, imiquimod, resiquimod (TLR7), small synthetic com-
pounds, imiquimod, resiquimod (TLR8), unmethylated CpG
oligodeoxynucleotide DNA (TLR9), profilin (TLR11), and
a bacterial ribosomal RNA sequence (TLR13). No ligands
are known for TLR10 and TLR12. TLRs are expressed on
different cells; however, all (except TLR12 which is exclusively
expressed on neurons) are expressed on the key antigen
presenting cells, monocytes, macrophages, DCs, and B cells.
An exponential amount of papers are being published empha-
sizing the enhanced potency of vaccines by incorporating
ligands that target TLRs on DCs with antigens, in animal
models. TLR2 [10–12], TLR4 [13–18], TLR7 [19], TLR8 [20],
and TLR9 [21] have been targeted with adjuvants which
demonstrated significant antigen-specific enhancement in
immune responses as compared to vaccinations without TLR
agonists.
IFN-gamma is a type II interferon produced by a variety
of leukocyte populations including type I helper T (Th1) cells,
natural killer (NK) cells, cytotoxic T lymphocytes (CTLs),
antigen-presenting cells (APCs) including macrophages and
DCs, andB cells. IFN-gamma is a potent immunomodulatory
cytokine which exerts multiple biological effects on a range
of cell types. Whilst typically known as an antiviral cytokine
due to its capacity to block viral replication [22, 23], IFN-
gamma has a broad range of functions on several arms of the
immune system, including skewing T cell responses towards
the type I helper T (Th1) cell phenotype [24, 25]. As a result,
cellular immunity mediated by innate NK cells, adaptive
CTLs, and macrophages [26]. IFN-gamma induces IL-12
and IFN-gamma production and inhibits IL-4 secretion and
functions, resulting in suppression of the Th2 response [27–
32]. These functional characteristics correspond evidently to
its role in antimicrobial and antitumor immunity [33].
IFN-gamma priming has been shown to enhance
macrophage activation through TLR ligation [34–37].
IFN-gamma promotes TLR ligand stimulation resulting
in enhanced production of microbicidal nitric oxide and
proinflammatory cytokines like IL-12. In addition to the
synergy with TLRs, IFN-gamma alone enhances antigen
processing and presentation in macrophages by upregulating
subunits essential for the MHC-class I and II antigen
presentation pathways [27–32]. Whilst the effect of IFN-
gamma with or without TLR ligands on macrophages has
been extensively studied, its adjuvanticity in DCs and its role
in DC-mediated T cell proliferative responses have not been
thoroughly clarified. In the current study, we investigate
the effect of IFN-gamma on DC functional maturation and
DC-meditated helper T cell activation, in the presence and
absence of TLR ligation (TLR4 (LPS), TLR2/6 (zymosan)
and TLR9 (CpG)).
2. Material and Methods
2.1. Animals. C57BL/6 and OT-II mice (aged 6–10 weeks)
used throughout this study were purchased from the animal
facilities of the Walter and Eliza Hall Institute (Melbourne,
Australia) or PAC in Alfred Medical Research and Education
Precinct (AMREP), Melbourne, Australia. C57BL/6 mice
were used as wild-type mice to evaluate IFN-gamma adju-
vanticity. OT-II mice were donors of OVA helper peptide-
specific CD4+ T cells. All mice were bred and maintained
under specific pathogen-free conditions and were used in
accordance with animal ethics guidelines. Ethics approval
was granted by AMREP Ethics Committee, and all mice were
treated and handled in accordance to the guidelines of the
National Health andMedical Research Council (NHMRC) of
Australia.
2.2. DCGeneration and Purification. Bonemarrow cells from
femurs and tibias of C57BL/6 mice were collected by flushing
with complete media (RPMI supplemented with 2% HEPES,
0.1mM 2-ME, 100U/mL penicillin, 100 𝜇g/mL streptomycin,
2mM glutamine, and 10% FCS) through 70 𝜇M cell strainers
and then were treated with red blood cell lysis buffer (0.15M
NH
4
Cl, 1mM KHCO
3
, and 0.1mM Na
2
EDTA) for 5mins
at room temperature. Washed cells were cultured in 24-
well plates in complete media supplemented with 10 ng/mL
GM-CSF and 10 ng/mL IL-4 (BD BioSciences, USA), at 5 ×
10
5 cells/well for 4-5 days. Cells were harvested by gently
pipetting and were either used as is for proliferation assays
(approximately 70% CD11c+) or were purified by magnetic
cell sorting. Briefly, cells were pelleted and incubated with
anti-CD11c MAC beads (400 𝜇L/108 cells) (Miltenyi Biotec,
Auburn, CA, USA) in the presence of 0.5% FCS and 2mM
EDTA in PBS at 4∘C for 15min. Cells were washed, resus-
pended, and purified using the autoMACS system (Miltenyi
Biotec) following manufacturer’s instructions. The percent-
age of CD11c+ cells purified in this manner was above 94% as
measured by FACS analysis.
2.3. DC Maturation. To precondition DC for IFN-gamma
studies, DC monolayers were incubated in complete media
containing 10 ng/mL IFN-gamma for 2 hours. Cells were then
washed and stimulated with either 1 𝜇g/mL LPS (derived
from Escherichia coli (0111 : B4) Sigma, San Diego, USA),
20𝜇g/mL zymosan A (from Saccharomyces cerevisiae, Sigma)
or 10 𝜇g/mL CpG1668 (GeneWorks, Adelaide, Australia) for
16 h at 37∘C. This procedure was previously optimized using
the DC2.4 cell line (data not shown). Cells (5 × 105) were
washed and resuspended with FITC-conjugated anti-CD40
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(FGK-45.5), anti-CD80 (16.10.A1), anti-CD86 (GL1), anti-
MHC-class II (IAb) (M5/114.15.2), all constructed in house, or
PE-conjugated anti-MHC-class I (BD BioSciences), together
with APC-conjugated anti-CD11c (BD Biosciences) at 4∘C for
30min. Cells were then analyzed for expression of surface
maturation markers by gating on live CD11c+ cells.
2.4. T Cell Purification. Splenocytes from C57BL/6 or OT-II
mice were collected, washed, and incubated in red blood cell
lysis buffer at room temperature for 5min. Cells were incu-
bated with antibodymix which contained in-house produced
rat anti-mouse Gr-1 (RB6-8C5), anti-CD11b (M1/70.15), anti-
erythrocyte (TER-119), and anti-MHC-class II (M5/114.15.2)
monoclonal antibodies at 4∘C for 30min. To purify CD4+
and CD8+ T cells, rat anti-mouse CD8-alpha (YTS169.4) and
anti-CD4 (GK1.5) were included in the antibodymix, respec-
tively. Labeled cells were depleted with 2 rounds of bead
separation. In each round, cells were incubated with goat
anti-rat Igmagnetic beads (8 beads/cell) (Qiagen,Melbourne,
Australia) at 4∘C for 25min. Cells were washed and those that
bound to the beads were removed by magnets. The purity of
T cells was at least 94%.
2.5. Antigen-Specific T Cell Proliferation. Purified DCs were
preconditioned with IFN-gamma (10 ng/mL) for 2 h and sub-
sequently treated with endotoxin-depleted OVA (40𝜇g/mL)
and LPS (1 𝜇g/mL) or zymosan (20𝜇g/mL) for 3 h. To eval-
uate the capacity of treated DCs to stimulate OVA-specific
helper T cells, titrated DCs (1–4 × 103) were seeded with
2 × 10
4 purified OT-II CD4+ T cells in quadruplicates in
96-well plates. Proliferation of T cells was monitored by the
addition of 1 𝜇Ci 3H-thymidine from day 1 to day 5. The
radioactivity was measured in counts per minute (CPM).
Peak proliferation of OT-II T cells on day 3 was compared.
2.6. T Cell Costimulation Assay. C57BL/6 DCs (1–4 × 103)
pretreated with IFN-gamma and/or TLR ligands were seeded
with 2 × 104 C57BL/6 CD4+ T cells in quadruplicates in
the 96-well plates precoated with 5 g/mL anti-CD3 (KT3-
1.1). T cell proliferation was monitored by 3H-thymidine
incorporation from day 2 to 7. Peak proliferation on day 5 was
compared.
2.7. InVivoDCMaturation. C57BL/6micewere injectedwith
LPS (2 𝜇g) or CpG intradermally into each footpad, with
or without IFN-gamma (2 ng). After 18 h, popliteal lymph
node cells were collected. All mice were treated and handled
as approved by the AMREP animal ethics committee, Mel-
bourne Australia and in accordance to the ethics guidelines
by NHMRC Australia. The maturation state of live CD11c+
DCs was determined by labelling with FITC-conjugated anti-
CD80 and anti-CD86 and analyzed by flow cytometry.
2.8. Statistical Analysis. All data are shown as the mean ±
standard error of the mean (SEM). The data generated in
this study were analyzed by student’s t-test. Significance of
difference was determined by the 𝑃 value (≤0.05).
3. Results
3.1. IFN-Gamma Enhances DC Maturation with or without
TLR Ligands. The ability of IFN-gamma to promote DC
maturation in vitro was assessed using day 5 bone marrow-
derived DC in the presence or absence of TLR ligands, LPS
(TLR4), and CpG (TLR9), by measuring cell surface expres-
sion of CD40, CD80, CD86, and MHC class II (Figure 1).
IFN-gamma alone had a moderate effect on the upregulation
of the activation markers, compared to untreated cells, most
notably causing an enhancement in the levels of CD86
and MHC II expression. Likewise, CpG alone induced low
levels of expression of the four surface markers compared to
untreated cells; however, this was augmented in the presence
of IFN-gamma, most notably, C40 and CD86. LPS strongly
induced DCmaturation as measured by the expression of the
activation markers, and in the presence of IFN-gamma, only
CD40 expression was further upregulated, albeit weak.
The ability of IFN-gamma to promote DC maturation in
vivo was similarly assessed, following hock injection of mice
with IFN-gamma in the presence or absence of TLR ligands
(Figure 2). CD11c+ DCs from the popliteal lymph nodes
showed increasedCD80 andCD86 expression following IFN-
gamma injection, compared to PBS-injected mice. Again,
LPS alone strongly induced the expression of both activation
markers which was not further augmented in the presence
of IFN-gamma. CpG alone had minimal effect on CD86
expression, but increased CD80 expression; however, the
inclusion of IFN-gamma further upregulated the expression
of both markers, indicating enhancement of bone marrow-
derived DC maturation.
3.2. IFN-Gamma Promotes DC Costimulation to CD4+ T
Cells Only in the Presence of TLR Ligands. CD80 and CD86
which both bind CD28 and CTLA-4 on the surface of T
cells providing regulatory signals leading to T cell activation
are two of several cell surface molecules involved in T cell
costimulation. Given the ability of IFN-gamma to upregulate
surface expression of CD80 and CD86 on DC, we next
investigated the capacity of these cells to promote T cell
costimulation resulting in proliferation. Day 5 bone marrow-
derived DCs were pretreated with IFN-gamma and TLR
ligands, LPS, or zymosan and then assessed for their ability
to co-stimulate proliferation of CD4+ T cells in the presence
of immobilized anti-CD3 antibody (Figure 3). IFN-gamma-
treated DCs alone were unable to induce CD4+ T cell
proliferation, in line with the low levels of CD80 and CD86
expression observed on these cells (Figures 1 and 3). However,
in the presence of TLR ligands, IFN-gamma-treated DC
promoted a high level of CD4+T cell proliferation, peaking at
day 5. At this time point, the correlation betweenDC number
and CD4+ T cell proliferation was assessed, with a positive
trend between DC number and CD4+ T cell proliferation
observed (Figure 3).
3.3. IFN-Gamma Enhances Antigen-Specific CD4+ T Cell
Response Only in the Presence of TLR Ligands. The ability
of IFN-gamma to potentiate antigen specific CD4+ T cell
proliferation was investigated. DCs were incubated with
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Figure 1: IFN-gamma enhances DC maturation with or without TLR ligands in vitro. C57BL/6 bone marrow cells were cultured with GM-
CSF to generate bone marrow derived DCs. At days 4-5, cells were preconditioned with IFN-gamma for 2 h (solid line) or no IFN-gamma
(dotted line), followed by LPS (TLR4 ligand) or CpG (TLR9 ligand) stimulation for 16 h. Cells were harvested and labelled with fluorescent
antibodies. Live CD11c+ cells were gated and analyzed for CD40, CD80, CD86, and MHC-class II expression. Data shown are representative
of at least two experiments. The shaded area represents cells stained with the respective secondary antibody.
IFN-gamma and pulsed with the model antigen ovalbumin
(OVA) and then incubated with CD4+ transgenic T cells
from OT-II mice which carry a transgenic CD4 T cell
receptor specific for theMHC class II restrictedOVApeptide,
OVA
323−339
[38].The ability of the DC to induce proliferation
of the OT-II CD4+ T cells in the presence and absence
of TLR ligation was monitored from days 1–5 (Figure 4).
Interestingly, the presence of TLR ligands alone induced
CD4+ T cell proliferation to OVA very poorly. However,
IFN-gamma pre-treatment dramatically enhanced antigen
presentation by DCs, as evident with the high levels of
CD4+ T cell proliferation. At the peak day of proliferation,
day 3, the effect of DC number on proliferative responses
was examined, with results again demonstrating a positive
correlation betweenDC number and themagnitude of CD4+
T cell proliferation.
4. Discussion
TLRs are essential receptors of the innate immune system
which stimulate a vast array of inflammatory responses and
eliminate invading pathogens. In addition, stimulation of
TLR by binding to their respective ligands has been shown
to lead to Th1, Th2, CD4+, and CD8+ T cell immune
responses [39]. Antigens in combination with TLR ligand
induce far superior immune responses compared to using
antigen alone in animal models. Agonists to TLR7 activate
plasmacytoid DCs (IFN-gamma, IFN-inducible protein, and
IFN-inducible T cell alpha chemoattractant secretion), and
TLR8 agonists activate myeloid DCs and monocyte-derived
DCs (TNFalpha, IL-12, and MIP-1alpha, IFN-gamma) and
upregulated CD40, CD80, and CD86 cell surface expression
[40]. TLR7/8 agonists conjugated to HIV-1 Gag protein
induce strong Th1/CD8+ T cell responses. Targeting TLR7
andTLR8 is effective in stimulating immune responses in vivo
[41]. In TLR9 knockout mice, DCs stimulated with CpG have
defective IL-12 and type-1 IFN secretion, even though Th1
and IFN-gamma responses were induced in TLR9 knockout
mice followingDNA immunizations [42]. TLR4 targeting has
been shown to upregulate cell surface co-stimulatorymarkers
(CD40, CD80, CD86), MHC molecules, and Th1 and Th2
cytokines on bone marrow-derived DCs [14–18]. Further,
totally synthetic vaccines which target TLR2 (Pam3CysSer)
carrying different antigens stimulate CD4+ and CD8+ T cell
and/or antibody responses [10–12]. Targeting TLR5 using
flagellin linked to antigens (ovalbumin (OVA), Listeriamono-
cytogenes antigen p60 peptides or listeriolysin) induced IgG1,
IgG2a antibodies, and protective CD8+ T cells responses in
mice [43].
Phenotypic maturation and T cell stimulation are two
functional attributes of DCs critical for immune induc-
tion, and their effective maturation into potent professional
antigen presenting cells has been shown to be dependent
on a number of critical cellular interactions, as well as by
cytokine and TLR signalling. IFN-gamma is a key player
in the development of T cell-mediated immunity and in
mounting an adaptive immune response against infection
or disease. In this study, we determined the ability of IFN-
gamma to augment DCmaturation and antigen presentation
induced by TLR signalling. Data demonstrate that whilst
IFN-gamma alone has a minor effect on DC functionality,
however, when used to treat DC before subsequent TLR
ligation, it significantly enhanced DC activation and T cell
stimulatory capacity.
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Figure 2: IFN-gamma enhances DC maturation with or without TLR ligands in vivo. C57BL/6 mice were injected with LPS (TLR4 ligand)
or CpG (TLR9 ligand) with (solid line) or without (dotted line) IFN-gamma intradermally using the Hock immunization protocol. At 18 h,
popliteal lymph cells were isolated. Live CD11c-high cells were analyzed for CD80 and CD86 expression. Data shown are representative of at
least two experiments. The shaded area represents cells stained with the respective secondary antibody.
In the present study, it is clear that IFN-gamma treatment
of bone marrow-derived DC followed by incubation with
the TLR4 (LPS) or TLR9 (CpG) agonists greatly enhanced
DC activation compared to TLR ligation alone. Most notably,
the upregulation of CD40 with LPS stimulation and CD86
with CpG stimulation was observed in in vitro cultures.
Similarly, IFN-gamma coinjected with TLR ligands was able
to promote DC activation in vivo, with DCs migrated from
the site of immunization to the popliteal lymph nodes
demonstrating increased expression of CD80 and CD86.The
heightened DC activation translated to a drastic increase in
T cell stimulatory capacity in both antigen independent and
dependent fashions.This is the first time that IFN-gammahas
been shown to have a combined effect with TLR ligation to
enhance DC activation and function. In contrast, the effect
of IFN-gamma on other APC populations has been well
characterized.
Much work has been done to study the effects of IFN-
gamma treatment on macrophages, with the consensus of
studies concluding that IFN-gamma primes macrophages
into a semiactive state which is highly receptive to activation
by a subsequent signal such as TLR ligation (for review
see [44]). For example, upregulation of CD40 and CD80 on
monocytes has been noted by IFN-gamma. Human acute
myeloid leukemia blasts express low levels of both co-
stimulatory molecules, demonstrating poor antigen present-
ing capacity. Incubation with IFN-gamma was found to up-
regulate CD40 and CD80 expression, and this was found
to be dependent on IRF-1 activation [45]. In addition, pre-
treatment of macrophages with IFN-gamma induced pro-
inflammatory cytokines, inducing an accumulation of IL-12
p40 and p35 mRNA, but only with subsequent TLR ligation
by LPS was IL-12 protein produced [46]. However, more
recent studies have demonstrated a cross talk between IFN-
gamma and TLR signalling pathways, with multiple elements
of the signalling pathways synergizing to induce expression
of proinflammatory factors [47]. In DC, TLR engagement is
an important factor in inducing DC maturation; however,
as with macrophages, it is likely that a combination of TLR
engagement and IFN-gamma signalling, thus mimicking the
inflammatory conditions in vivo, is necessary to produce
optimal DC activation. Indeed, the current studies show
that the combination of both signals not only promotes the
expression of activation markers but also corresponds with
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Figure 3: IFN-gamma enhances DC costimulation only when the TLR ligand is present. Days 4-5 bonemarrow cultures preconditioned with
IFN-gamma (black symbols) or no IFN-gamma (open symbols) for 2 h was stimulated with LPS (TLR4 ligand) or zymosan (TLR2 ligand)
for 16 h. DCs were purified via the AutoMacs system as described in Section 2. Titrated bone marrow-derived DCs (1 × 103–4 × 103) were
incubated with 2 × 103 CD4 T cells in quadruplicates in 96-well plates that were precoated with anti-CD3. Cell proliferation was monitored
from day 2 to day 7. Proliferation kinetics was exemplified when DCs were seeded at 2× 103 (a, b, c). As proliferation in general peaked at day
5, it was compared across DC titrations (d, e, f). Data shown are representative of two separate experiments. 𝑃 < 0.05 in LPS and zymosan
groups at all points except time point 2 days, based on quadruplicate values.
increased signalling to CD4+ T cells, in both nonspecific and
antigen-specific fashions.
Various signals can promote DC maturation, including
direct cell-to-cell contact, cytokine signalling, and TLR
signalling from microbial stimuli. Reports investigating the
bidirectional cross talk between NK cells and DC have indi-
cated that DC can activate NK cells which in turn enhance
DC maturation [48]. In the presence of direct cell-to-cell
contact, strong DC maturation was observed as indicated
by CD86 expression; however, both IFN-gamma and TNF-
alpha produced by the activated NK cells were found to
enhance the levels of CD86 expression, although on their own
the cytokines had little effect [48]. Likewise, in the current
studies, IFN-gamma alone had little effect on the induction of
DCmaturationmarkers CD40, CD80, CD86, andMHC class
II. In the presence of a secondary stimuli via TLR ligation,
however, the upregulation of the cell surface markers was
enhanced following IFN-gamma priming.
In other studies, cultures of splenic DC with IFN-
gamma upregulated expression of CTLA-4 counter receptor
(however any counter receptor theymeasured in these studies
is unclear), but not ICAM-1, heat stable antigen or MHC
Journal of Drug Delivery 7
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Figure 4: IFN-gamma enhances DC antigen presentation via MHC-class II, only in the presence of a TLR stimulus. Day 4 bone marrow
cultures preconditioned with IFN-gamma for 2 h were pulsed with OVA in the presence of LPS (TLR4 ligand) or zymosan (TLR2 ligand) for
3 h. DCs were purified as described in Section 2. Titrated bone marrow-derived DCs (1 × 103–4 × 103) were incubated with 2 × 103 CD4 T
cells in quadruplicates in 96-well plates. Cell proliferation was monitored from day 1 to day 5. Proliferation kinetics was exemplified when
DCs were seeded at 2 × 103 (a, b, c). Peak proliferation at day 3 was compared across DC titrations (d, e, f). Data shown are representative of
two separate experiments. 𝑃 < 0.05 in all LPS and zymosan groups at all points, based on quadruplicate values.
class I or class II [49]. However, despite the upregulation
of this T cell receptor co-stimulatory signal, the ability of
IFN-gamma treatedDC to induce T cell proliferation was not
enhanced. Similarly, another study investigating the effects of
cytokine pre-treatment on DC function demonstrated that
when DCs were cultured overnight with IFN-gamma and
used in mixed lymphocyte reactions, the T cell proliferation
was in fact lower than using untreated DC [50]. While the
DC populations studied in these reports were different to
the bone marrow-derived DC used in the current studies,
the results clearly substantiate the current findings that
additional costimulation (in the form of TLR ligation) is
necessary to promote the adjuvanticity of IFN-gamma.
The synergy between IFN-gamma and TLR ligands
suggest that such combination is likely to be more highly
beneficial to boost immune responses than IFN-gamma
or TLR ligand alone in therapeutic settings for diseases,
including cancer. Here, we unravel the adjuvant effect of
IFN-gamma on DCmaturation and T cell stimulation which
are two important steps to achieve adaptive immunity for
diseases, including cancer.
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